Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3518 participants.
Also called NCT07683923
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,518 participants
- Registry
-
NCT07683923 -
2025-523985-26-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada, Germany, Netherlands, Sweden, United Kingdom
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07683923. Randomized; single masking; primary purpose treatment. Start 2027-03-01 (anticipated); primary completion 2033-02-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial
- Acronym
- SCAD-ALIGN
- Condition
- SCAD
- Condition
- ACS (Acute Coronary Syndrome)
- Intervention (Drug)
- Acetylsalicylic acid ASA
- Intervention (Drug)
- ASA plus Clopidogrel
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Collaborator
- National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK
- Collaborator
- Gesellschaft für Therapieforschung mbH
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator
- Davos Life Science Pte Ltd
Record details
- Record id
cardio:ct-nct07683923- Content hash
6c74cef06e5725310b4165d9ed2934235ea444b3c8220e4cb597ebdbf6f68958